All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Rare variants of genes encoding the cardiac sodium channel have been linked with atrial fibrillation (AF). For instance, mutations in the *SCN5A* gene that encodes the alpha-subunit of the sodium current (Nav1.5) have been found in 9% of an unselected AF population and in 6% of patients with lone AF.\[[@pone.0183690.ref001]\] Mutations of the *SCN1B --SCN4B* genes that encode the modifying beta-subunits of the Navß1-ß4 have been detected in an additional 2%.\[[@pone.0183690.ref002], [@pone.0183690.ref003]\] Other genes play an important role for the generation of a healthy Nav1.5 current by coding for accessory channel anchoring or trafficking proteins. Mutations in four of these genes, i.e. *GPD1L*, *MOG1*, *SNTA1*, *CAV3* have been linked with AF \[[@pone.0183690.ref004]\] and long QT syndrome (LQTS),\[[@pone.0183690.ref005], [@pone.0183690.ref006]\] Brugada syndrome (BrS) \[[@pone.0183690.ref007]\] or sudden infant death syndrome (SIDS) \[[@pone.0183690.ref008]\].

However, current expert consensus does not support genetic testing in AF. This recommendation is in part based on the fact that "there is no prognostic or therapeutic impact derived from AF genetic test result".\[[@pone.0183690.ref009]\] Since there are no studies available supporting this recommendation we sought to investigate the frequency and potential impact of rare sodium channel or associated compound variants on rhythm outcome of catheter ablation of AF.

Methods {#sec005}
=======

Study population {#sec006}
----------------

The study included 137 consecutive patients of Caucasian ancestry with drug refractory paroxysmal or persistent lone AF enrolled in the Leipzig Heart Center AF Ablation and Genetics Registry, who underwent AF radiofrequency ablation. The patient characteristics are summarized in [Table 1](#pone.0183690.t001){ref-type="table"} and [S1 Table](#pone.0183690.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0183690.t001

###### Rare variants in AF.

![](pone.0183690.t001){#pone.0183690.t001g}

  --------------------------------------------------------------------------------------------------------------
  Gene                                    n    Locus of mutation                       NCBI Reference Sequence
  --------------------------------------- ---- --------------------------------------- -------------------------
  *SCN5A*\                                1\   SCN5A/Exon2/c.73G\>A/p.E25K\            NM_000335.4\
                                          1\   SCN5A/Exon9/c.1036G\>A/p.E346K\         
                                          1    SCN5A/Exon17/c.3190G\>A/p. E1064K       

  *SCN1B*\                                3\   SCN1B/Exon3_ext/c.448+193G\>A/p.R214Q   NM_199037.3
                                          2                                            

  SCN1B/Exon3_ext/c.448+321G\>A/p.G257R                                                

  *SCN4B*                                 1    SCN4B/Exon6/c.632C\>G/p.T211R           NM_174934.3

  *GPD1L*\                                4\   GPD1L/Exon4/c.370A\>G/p.I124V\          NM_015141.3\
                                          1\   GPD1L/Exon3/c.267C\>A/p.D89E\           
                                          1    GPD1L/Exon4/c.391C\>A/p.L131M           

  *MOG1*                                  3    MOG1, Exon 1_2/c.181G\>T/p.E61X         NM_016492.4

  *SNTA1*\                                1\   SNTA1/Exon4/c.787G\>T/p.A263S\          NM_003098.2\
                                          2    SNTA1/Exon3/c.556C\>T/p.S189L           

  *CAV3*                                  1    CAV3/Exon2/c.433G\>A/p.V145M            NM_033337.2
  --------------------------------------------------------------------------------------------------------------

Paroxysmal AF was defined as self-terminating episodes of AF within 7 days after onset documented by ECG or an ambulatory ECG monitor. Persistent AF was defined as an AF episode either lasting longer than 7 days or requiring drug or direct current cardioversion for termination.

In all patients, transthoracic and transesophageal echocardiography was performed prior to catheter ablation. Left atrial diameter and left ventricular ejection fraction were determined using standard measurements and a left atrial thrombus was excluded. All class I or III antiarrhythmic medications with the exception of amiodarone were discontinued at least 5 half-lives before the procedure.

The study was approved by the institutional review board (Medical Faculty, Leipzig University) and performed in agreement with the declaration of Helsinki. All patients provided written informed consent for study participation.

Genotyping {#sec007}
----------

Whole blood was collected for genomic DNA extraction and analysis from all subjects. We directly sequenced the coding regions of high priority candidate ion channel genes *SCN5A* (sodium channel, voltage-gated, type V, alpha subunit), *SCN1B* (sodium channel, voltage-gated, type I, beta subunit), *SCN2B* (sodium channel, voltage-gated, type II, beta subunit), *SCN3B* (sodium channel, voltage-gated, type III, beta subunit), and *SCN4B* (sodium channel, voltage-gated, type IV, beta subunit) as well as non-ion channel candidate genes *SNTA1* (syntrophin, alpha 1), *CAV3* (caveolin 3), *MOG1* (RAN guanine nucleotide release factor) and *GPD1L* (glycerol-3-phosphate dehydrogenase 1-like protein).

Screening for variants was performed by PCR amplification of coding regions and flanking intronic sequences followed by direct sequencing of amplicons on an ABI prism 3730 DNA Sequence Detection System. All variants were validated by re-sequencing an independent PCR-generated amplicon from the subject.

Variant selection and functional analysis {#sec008}
-----------------------------------------

All non-synonymous variants (missense, nonsense, frame-shift, and splice-site) were screened against dbSNP build 137, National Heart, Lung, Blood Institute (NHLBI) Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC, [http://exac.broadinstitute.org](http://exac.broadinstitute.org/)). Variants were defined as being rare if a minor allele frequency \< 1% was reported in all of the interrogated databases and variants absent from these were defined as being novel. Single base conservation scores and predicted functional effects were evaluated by PhastCons, Genomic Evolutionary Rate Profiling (GERP), Grantham scores, and PolyPhen2 using the SeattleSeq Genomic Variation Server and are presented in [Table 2](#pone.0183690.t002){ref-type="table"} and [S2 Table](#pone.0183690.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0183690.t002

###### Patient characteristics.

![](pone.0183690.t002){#pone.0183690.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                 Total   Variant\    Variant non-carriers\   P-value
                                                                                                         carriers\   (N = 115)               
                                                                                                         (N = 22)                            
  ---------------------------------------------------------------------------------------------- ------- ----------- ----------------------- ---------
  Age, yrs                                                                                       51±11   52±14       51±11                   0.595

  Male (%)                                                                                       93      96          93                      0.676

  Persistent AF (%)                                                                              34      41          32                      0.427

  AF history, months                                                                             73±66   74±74       72±65                   0.868

  BB[^†^](#t002fn001){ref-type="table-fn"} / CCB[^‡^](#t002fn002){ref-type="table-fn"} use (%)   80      86          78                      0.388

  Digitalis use (%)                                                                              10      18          9                       0.241

  AAD[^§^](#t002fn003){ref-type="table-fn"} use (%)                                              43      45          43                      0.805

  LAD[^¶^](#t002fn004){ref-type="table-fn"}, mm                                                  42±6    43±5        42±6                    0.604

  LVEF[^\#^](#t002fn005){ref-type="table-fn"} (%)                                                61±11   63±11       61±11                   0.455
  ----------------------------------------------------------------------------------------------------------------------------------------------------

^†^BB---beta blockers

^‡^CCB---calcium channel blockers

^§^AAD---antiarrthythmic drugs

^¶^LAD---left atrial diameter

^\#^LVEF---left ventricular ejection fraction.

Catheter ablation {#sec009}
-----------------

Left atrial catheter ablation was performed using a previously described approach.\[[@pone.0183690.ref010]\] In brief, patients were studied under deep propofol sedation with continuous invasive monitoring of arterial blood pressure and oxygen saturation. Non-fluoroscopic 3D catheter orientation, CT image integration, and tagging of the ablation sites were performed using Ensite NavX, Ensite Velocity (St. Jude Medical, St. Paul, MN, USA) or CARTO 3 (Biosense Webster, Diamond Bar, CA, USA). Trans-septal access and catheter navigation were performed with a steerable sheath (Agilis, St. Jude Medical, St. Paul, MN, USA). Patients presenting with AF at the beginning of the procedure were electrically cardioverted and ablation was performed during sinus rhythm (i.e. AF termination with ablation was not attempted). In all patients circumferential left atrial ablation lines were placed around the antrum of the ipsilateral pulmonary veins (irrigated tip catheter, pre-selected tip temperature of 48°C, and maximum power of 30--50 W). In patients with persistent AF, additional linear lesions were added at the left atrial roof, the basal posterior wall and the left atrial isthmus. Ablation of complex fractionated electrograms was not performed.

After circumferential line placement, voltage and pace mapping along the ablation line were used to identify and close gaps. The isolation of all pulmonary veins with bidirectional block was verified with a multipolar circular mapping catheter and was defined as the procedural endpoint.

Follow-up {#sec010}
---------

After ablation, class I and III antiarrhythmic drugs were not reinitiated. Oral anticoagulation was prescribed for 6 months, and proton pump inhibitors were added for 4 weeks. All patients were followed in the outpatient clinic for 12 months after the ablation. During this follow-up period, 7-day Holter ECG recordings were performed 3, 6 and 12 months after the ablation. Additional ECGs and Holter ECG recordings were obtained when patients' symptoms were suggestive of AF. AF recurrence was defined as a documented AF episode lasting longer than 30 seconds between 3 and 12 months after the ablation (thus, including a 3-month "blanking period"). All patients with sustained early recurring AF underwent direct cardioversion. Additional drug administration was left to the discretion of the treating physician.

Statistical analysis {#sec011}
--------------------

Continuous variables are presented as mean values ± one standard deviation and categorical variables as frequencies. Comparison of continuous variables was performed using the unpaired Student's t-test and of categorical variables using the Pearson chi-square test. A two-sided p-value \< .05 was considered as statistically significant.

Considering a case--control ratio of 1:5 and assuming large variant effects, a difference of 57% versus 25% AF recurrence rates could have been detected with power of 80%.

Results {#sec012}
=======

Sodium channel and associated compound rare variants in AF {#sec013}
----------------------------------------------------------

In 22 patients (16%), we identified 3 rare non-synonymous variants in *SCN5A*, 2 in *SCN1B*, 1 in *SCN4B*, 1 in *CAV3*, 3 in *GPD1L*, 2 in *SNTA1* and 1 in *MOG1* ([Table 1](#pone.0183690.t001){ref-type="table"}). Variant details and *in-silico* prediction is summarized in [S2 Table](#pone.0183690.s002){ref-type="supplementary-material"}.

There were no significant differences in clinical characteristics between variant carriers and non-variant carriers ([Table 2](#pone.0183690.t002){ref-type="table"}). The individual clinical and ECG characteristics of the variant carriers are summarized in [S1 Table](#pone.0183690.s001){ref-type="supplementary-material"}. None of the patients exhibited a typical BrS pattern on 12-lead ECG or showed a prolonged QT interval duration suggestive of LQTS. Patients' history and family history was not suspicious with respect to syncope, aborted sudden cardiac death or SIDS. Three patients each had a brother with AF who either had died or did not consent for genetic testing.

### Outcome of AF catheter ablation {#sec014}

Complete pulmonary vein isolation as a procedural end point was achieved in all cases. Eleven patients did not have a complete follow-up and were therefore excluded from the analysis. AF recurrence within the first week (ERAF) and between 3 and 12 months (LRAF) were observed in 49% and 48%, respectively.

Patients with AF recurrence are compared to patients without AF recurrence in [Table 3](#pone.0183690.t003){ref-type="table"}. There were no differences in clinical characteristics between patients with and without ERAF and LRAF. Patients' variant carrier status had also no impact on the recurrence of AF ([Fig 1](#pone.0183690.g001){ref-type="fig"}). In patients with LRAF, reablation rates were comparable between both groups (78% in variant carriers versus 68% in variant non-carriers, p = .709). All of those patients had reconnected pulmonary veins.

![AF recurrence stratified by variant carrier status.](pone.0183690.g001){#pone.0183690.g001}

10.1371/journal.pone.0183690.t003

###### Comparison of patients with and without early (ERAF) and late recurring AF (LRAF).

![](pone.0183690.t003){#pone.0183690.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                             ERAF+\        ERAF-\        P\      LRAF+\        LRAF-\        P\
                                                                                             n = 62        n = 65        value   n = 62        n = 67        value
  ------------------------------------------------------------------------------------------ ------------- ------------- ------- ------------- ------------- ---------
  Male %                                                                                     97            94            0.680   94            94            \>0.999

  Persistent AF %                                                                            32            28            0.613   34            30            0.624

  AF history (months)                                                                        74 ± 63       77 ± 72       0.958   82± 73        66 ± 60       0.251

  Age (years)                                                                                52 ± 11       50 ± 12       0.380   53 ± 11       50 ± 11       0.131

  BB[^†^](#t003fn001){ref-type="table-fn"}/CCB[^‡^](#t003fn002){ref-type="table-fn"} use %   86            78            0.285   86            78            0.251

  Digitalis use %                                                                            11            9             0.724   13            9             0.471

  Previous AAD[^§^](#t003fn003){ref-type="table-fn"} use %                                   44            45            0.842   48            40            0.355

  LAD (mm)                                                                                   43 ± 6        41 ± 5        0.323   42 ± 6        42 ± 6        0.945

  LVEF (%)                                                                                   61 ± 9        61 ± 13.0     0.480   62 ± 8        61 ± 13       0.933

  IVSd[^¶^](#t003fn004){ref-type="table-fn"} (mm)                                            12 ± 2        12 ± 2        0.816   12 ± 2        12 ± 2        0.667

  LVED[^\#^](#t003fn005){ref-type="table-fn"} (mm)                                           50 ± 6        48 ± 9        0.219   49 ± 9        49 ± 6        0.396

  Additional linear lesions (%)                                                              53            44            0.286   56            47            0.323

  Ablation time (s)                                                                          3177 ± 1433   3158 ± 1117   0.950   3472 ± 1501   3005 ± 1174   0.158

  Variant carriers %                                                                         13            16            0.662   15            16            0.766
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^BB---beta blockers

^‡^CCB---calcium channel blockers

^§^AAD---antiarrthythmic drugs

^¶^IVSd---interventricular septal enddiastolic dimension

^\#^LVED---left ventricular end diastolic diameter.

Discussion {#sec015}
==========

Main findings {#sec016}
-------------

To the best of our knowledge, this is the first study to analyze the impact of rare variants in cardiac sodium channel and associated compound genes on outcome after catheter ablation for AF. Analysis of 137 patients with lone AF revealed a prevalence of sodium channel and associated compound gene rare variants of 16%, but no large impact on outcome of ablation.

Rare variants in genes responsible for the sodium current in AF {#sec017}
---------------------------------------------------------------

The voltage-gated cardiac sodium channel is a multiprotein complex in which accessory proteins interact with the alpha-subunit to regulate its gating, cellular localization, intracellular transport, and degradation. It conducts the inward sodium current (INa) that initiates action potential depolarization and is essential for action potential propagation in the heart but also influences repolarization and refractoriness.\[[@pone.0183690.ref011]\]

Several genetic variants in *SCN5A*, causing both loss and gain of INa, have been associated with lone AF,\[[@pone.0183690.ref001], [@pone.0183690.ref012]\] thereby expanding the number of phenotypes associated with rare variants in the *SCN5A* gene. Although the fundamental mechanisms of each of these *SCN5A* associated disorders may differ considerably, phenotypic overlap exists, including individuals with both the LQTS and BrS \[[@pone.0183690.ref013]\] and those with both BrS and conduction system disease.\[[@pone.0183690.ref014]\] Also, up to 3% of patients with LQTS and 22% with BrS suffer from AF.\[[@pone.0183690.ref015], [@pone.0183690.ref016]\]

Selection of other candidate genes (*SCN1B-4B*, *GPD1L*, *MOG1*, *SNTA1*, *CAV3*) was based on previously described associations between variants in these genes and AF, LQTS or BrS. The encoded accessory proteins play an important role in the generation of healthy cardiac sodium current. The protein encoded by the *GPD1L* gene is found in the cytoplasm, associated with the plasma membrane, where it binds the sodium channel, voltage-gated, type V, alpha subunit. Rare variants in this gene are a cause of BrS type 2 \[[@pone.0183690.ref007]\] as well as SIDS \[[@pone.0183690.ref008]\] by decreasing INa through a reduction in *SCN5A* cell surface expression.\[[@pone.0183690.ref007]\]

The *MOG1* gene plays an important role in sodium channel trafficking by increasing plasma membrane expression of Na(v)1.5 and sodium current (I(Na)) density. A disturbed function due to rare variants and resulting loss-of/reduced sodium current has been shown to cause a BrS type 11, sick-sinus syndrome and lone AF.\[[@pone.0183690.ref004], [@pone.0183690.ref017], [@pone.0183690.ref018]\]

The N-terminal domain of the syntrophin protein encoded by the *SNTA1* gene interacts with the C-terminus of the pore-forming alpha subunit of the cardiac sodium channel Nav1.5. This gene is a susceptibility locus for LQTS type 12 and SIDS due to an increase in late sodium current.\[[@pone.0183690.ref019], [@pone.0183690.ref020]\]

Caveolin-3, encoded by *CAV3* is identified as an important negative regulator for cardiac late INa via nNOS dependent direct S-nitrosylation of *SCN5A*, however *CAV3* mutations increase late INa and cause LQTS type 9.\[[@pone.0183690.ref021], [@pone.0183690.ref022]\]

In our cohort, 16% patients were carriers of rare variants. However, aside from lone AF they did not express any particular ECG phenotype, i.e. PR prolongation, LQTS or BrS patterns. In order to predict functionality we reported the results of recognized *in-silico* tools. However, the accuracy of these tools is limited, especially for the sodium channel.\[[@pone.0183690.ref023]\] There were contradictory results between tools and some variants that had previously been reported in association with BrS \[[@pone.0183690.ref007]\] and SIDS \[[@pone.0183690.ref008]\] were reported as "benign". In that context, it also needs to be pointed out that a comprehensive mutational analysis of 829 unrelated subjects estimated that about 5% of healthy individuals harbor a rare non-synonymous variant in *SCN5A*.\[[@pone.0183690.ref024]\] Thus, it remains elusive whether or not those rare variants were disease causing.

Associations between genotype and AF ablation outcomes {#sec018}
------------------------------------------------------

Over the last 5 years, several studies have analyzed possible associations between common genetic variants and AF ablation outcomes. Our group was the first to report an association between common AF-susceptibility alleles on chromosome 4q25 and rhythm outcomes of catheter ablation.\[[@pone.0183690.ref025]\] Meanwhile, this finding has been replicated by another single-center study \[[@pone.0183690.ref026]\] and very recently by a meta-analysis including 991 patients from 3 centers.\[[@pone.0183690.ref027]\]

Several other, smaller studies have used a candidate gene approach focusing on different AF pathophysiological pathways. So far, polymorphisms in the soluble epoxide hydrolase gene (*EPHX2*),\[[@pone.0183690.ref028]\] the heme oxygenase-1 gene (*HO-1*),\[[@pone.0183690.ref029]\] the angiotensin-converting enzyme gene (*ACE*),\[[@pone.0183690.ref030]\] the interleukin-6 receptor gene (*IL6R*),\[[@pone.0183690.ref031]\] and the angiotensinogen gene (*AGT*) \[[@pone.0183690.ref032]\] have been found to associate with recurring atrial arrhythmias but replication studies are lacking.

All these studies point to the potential role of genotypes for the individual stratification of therapeutic interventions in AF patients with the goal of improving rhythm outcome and increasing patient safety for instance through better patient selection, tailored ablation and post ablation management.

However, unselected screening for rare variants was not helpful for this purpose in our cohort consequently supporting current recommendations \[[@pone.0183690.ref009]\] and clinical practice. Ablation outcomes in our cohort that represents the largest study with known rare variant carrier status were in agreement with two previous case series in 9 and 5 BrS patients in whom mutations were, however, not reported.\[[@pone.0183690.ref033], [@pone.0183690.ref034]\]

Limitations {#sec019}
-----------

Although we included patients with lone AF, left atrial diameter was somewhat enlarged with low prevalence of diastolic dysfunction with no differences among both groups. Overall we found no large impact of rare variants on outcome of de-novo catheter ablation. Moreover, although reablation rates were comparable with all patients showing reconnected pulmonary veins, the sample size of this subgroup is rather small, therefore, no meaningful comparison of impact on subsequent outcome or AF mechanisms can be made. However, this does not rule out that private mutations may play a role in the outcome of therapeutic interventions for AF. While rare variants are more likely to be associated with large effect sizes, we do acknowledge that functional studies or co-segregation data are required to support disease-causality. Importantly, co-segregation could not be assessed (e.g. 3 brothers were not screened). Moreover, additional functional analysis on any of the detected rare non-synonymous mutations that have not been described previously was not performed. Hence, we are unable to determine whether the identified variants are pathogenic or benign or have smaller effects that could not be detected with this sample size. Although we did not include a non-AF sample, the majority of variants are very rare in reference samples. However, there is no phenotype data available and consequently, controls may in fact contain AF cases or other heart disease.

While we re-sequenced several high priority candidate AF genes, we did not perform whole exome/next generation sequencing. Therefore, we cannot exclude the possibility of our findings being influenced by variants residing in genes that were not screened. It is also possible that by evaluating coding regions only we may have missed potentially important variants in non-coding regions. Lastly, by focusing on rare variants only, we are unable to assess the effects of common variants including combinations of variants, with small or intermediate effects. Furthermore it should be noted that this study applies only to males, since they represent \>90% of the study population.

Conclusions {#sec020}
===========

Rare variants of genes encoding the cardiac sodium channel and associated compounds are frequently found in lone AF but seem not to impact on outcome of AF catheter ablation. This finding is in agreement with current recommendations not to screen for rare variants for the ablation outcome in AF. Nevertheless, it may at least be helpful for understanding AF mechanisms and larger studies are needed to further explore the possible association between genotype and response to AF therapies.

Supporting information {#sec021}
======================

###### Individual clinical (top), echo- and electrocardiographic (bottom) characteristics of variant carriers.

(DOCX)

###### 

Click here for additional data file.

###### Prevalence of rare variants in other cohorts and functional predictions.

(DOCX)

###### 

Click here for additional data file.

AF

:   atrial fibrillation

LQTS

:   long QT syndrome

BrS

:   Brugada syndrome

SIDS

:   sudden infant death syndrome

*SCN5A*

:   sodium channel, voltage-gated, type V, alpha subunit

*SCN1B*

:   sodium channel, voltage-gated, type I, beta subunit

*SCN2B*

:   sodium channel, voltage-gated, type II, beta subunit

*SCN3B*

:   sodium channel, voltage-gated, type III, beta subunit

*SCN4B*

:   sodium channel, voltage-gated, type IV, beta subunit

*SNTA1*

:   syntrophin, alpha 1

*CAV3*

:   caveolin 3

*MOG1*

:   RAN guanine nucleotide release factor

*GPD1L*

:   glycerol-3-phosphate dehydrogenase 1-like protein

ERAF

:   early recurrence of atrial fibrillation

LRAF

:   late recurrence of atrial fibrillation

INa

:   inward sodium current

*EPHX2*

:   soluble epoxide hydrolase gene

*HO-1*

:   heme oxygenase-1 gene

ACE

:   angiotensin-converting enzyme gene

*IL6R*

:   interleukin-6 receptor gene

AGT

:   angiotensinogen gene

BB

:   beta blockers

CCB

:   calcium channel blockers

AAD

:   antiarrthythmic drugs

LAD

:   left atrial diameter

LVEF

:   left ventricular ejection fraction

IVSd

:   interventricular septal enddiastolic dimension

LVED

:   left ventricular end diastolic diameter
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